Sumanta Kumar Pal, MD, FASCO - Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XZU865. CME/MOC/NCPD/AAPA/IPCE credit will be available until February 25, 2025.Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Kidney Cancer Research Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through medical education grants from AVEO Pharmaceuticals, Inc., Bristol Myers Squibb, Eisai Inc., Exelixis, Inc., and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSumanta Kumar Pal, MD, FASCO, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Allogene Therapeutics; CRISPR Therapeutics; Eisai Co., Ltd.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Pfizer all paid to institution.Faculty/PlannerPedro C. Barata, MD, MSc, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; AVEO Pharmaceuticals, Inc; Bristol Myers Squibb; Clovis Oncology; EMD Serono; Eisai Co., Ltd.; Exelixis, Inc.; Ipsen Biopharmaceuticals, Inc.; Pfizer; and Sanofi.Grant/Research Support from EMD Serono and Exelixis, Inc.Speakers Bureau participant with Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; and Sanofi.Faculty/PlannerDavid F. McDermott, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerTian Zhang, MD, MHS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravive; AstraZeneca; AVEO Pharmaceuticals, Inc.; Bayer Corporation; Bristol Myers Squibb; Caris Life Sciences; Eisai Co., Ltd.; EMD Serono; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seagen Inc.Grant/Research Support from ALX Oncology; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; and Tempus.Other Financial or Material Support for leadership or fiduciary role in Kidney Cancer Association (KCA) Medical Steering Committee; Kidney Cancer Research Alliance (KCCure) Scientific Advisory Board; and National Cancer Institute (NCI) Steering Renal Task Force.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.